Diabetic kidney disease (DKD) is associated with significant morbidity and mortality.
Identifying new treatments for DKD to be used alone or in combination with other therapies is
a high priority. Inflammation plays a key role in DKD and targeting pro-inflammatory lipid
mediators called leukotrienes may represent a promising therapy for DKD. The current proposal
will investigate whether montelukast, a leukotriene antagonist, reduces proteinuria and
improves vascular function and arterial stiffness in patients with DKD.